News for Celyad Oncology SA (CYAD)

The IDH inhibitors market is expected to grow significantly in the coming years. This is due to the rising occurrence of IDH-mutated cancers, such as acute...

T : +32 3 230 58 40 Uitbreidingstraat 72/1 ...

Celyad Oncology reports FY2023 revenue of €0.1M and a net loss of €8.5 million, reflecting challenging financial performance in the oncology sector.

Celyad Oncology Reports Full Year 2023 Financial Results and Recent Business Highlights

And on we go, turning rocks and kissing frogs in the Belgian stock market. This batch of 20 randomly selected stocks yielded 4 watch list candidates, among them a stock I owned in the past. So far, the "Expert Market" is a littlebit disappointing. For many of the companies there it is really hard to…

Sep 05, 2023 / 11:00AM GMTOperator Greetings. Welcome to Celyad Oncology's half-year 2023 earnings conference call. (Operator Instructions) Please note that thi

Mar 24, 2023 / 12:00PM GMTOperator Greetings. Welcome to the Celyad Oncology full-year 2022 earnings conference call. (Operator Instructions) Please note that t

Mar 25, 2022 / 12:00PM GMTOperator Welcome to the Celyad Oncology second half 2021 earnings conference call. (Operator Instructions) Please note this event is b

Aug 05, 2022 / 12:00PM GMTOperator Greetings and welcome to the Celyad Oncology first half 2022 financial results. (Operator Instructions) As a reminder, this c

Aug 04, 2021 / 12:00PM GMTOperator Good morning, and welcome to the Celyad Oncology first-half 2021 earnings conference call. (Operator Instructions) Please not

IMMUNOPRECISE ANTIBODIES LTD. Unit 3204 - 4464 Markham Street Victoria, BC V8Z 7X8 NOTICE OF ANNUAL GENERAL MEETING OF...

/PRNewswire/ -- The cell therapy market size is expected to grow by USD 31.04 billion from 2022 to 2027. In addition, the momentum of the market will progress...

[222 + Pages Report] According to a market research study published by Zion Market Research, the demand analysis of Global CAR T-Cell Therapy Market size &...

/PRNewswire/ -- The CAR T-cell therapy market is expected to grow by USD 1,999 million from 2022 to 2027, progressing at a CAGR of 13.44% as per the latest...

The acute myeloid leukemia market has a promising outlook with emerging therapies. The overall dynamics of the acute myeloid leukemia market are...

NEW YORK, July 06, 2023 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the ordinary shares of Puhui Wealth Investment...

The massacre, stock by stock, all 1001 of them, listed right here.

Gainers NeuroMetrix, Inc. (NASDAQ: NURO) shares jumped 76.3% to close at $5.50 on Thursday after the company announced the FDA has granted De Novo authorization to market the Quell neuromodulation device as an aid for reducing the symptoms of fibromyalgia.